<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500110</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0112</org_study_id>
    <nct_id>NCT00500110</nct_id>
  </id_info>
  <brief_title>Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer</brief_title>
  <official_title>Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation,
      Imatinib and Docetaxel (HID) in high-risk localized prostate cancer.

      Secondary Objectives:

        1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant
           HID and radical prostatectomy in high-risk localized prostate cancer.

        2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor
           Receptor (PDGFR) pathway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel is a drug that was designed to help kill cancer cells. Imatinib mesylate is a drug
      designed to block cancer cells from growing and dividing. Hormonal treatment with Lupron
      (leuprolide) or Zoladex (goserelin acetate) is used to lower testosterone levels in the body
      because prostate cancer cells need testosterone to survive. All patients will have their
      prostate gland removed after treatment with these drugs.

      Before treatment starts, you will be asked questions about your medical history and have a
      complete physical examination. You will have blood drawn (2 tablespoons) for routine blood
      tests. You will be asked questions about any medications you are currently taking and have
      taken in the past. You will have an electrocardiogram (ECG - a test that measures electrical
      activity of the heart). As part of your standard care for prostate cancer, you will also have
      a computed tomography (CT) scan (or magnetic resonance imaging ((MRI)) scan) of the abdomen
      and pelvis along with a bone scan (x-rays of the bones) to see if the prostate cancer has
      moved to other parts of your body.

      For this study, you will receive hormone injections to lower the levels of testosterone in
      the blood. You will also take imatinib mesylate capsules by mouth and receive treatment with
      docetaxel by vein to help kill the cancer cells before surgery.

      You will receive hormone therapy with either leuprolide or goserelin acetate injections,
      whichever your doctor feels will give you the most benefit. The hormone injections will be
      given every other month or every 3 months. During treatment with the hormones, you will also
      take an anti-androgen drug called Casodex (bicalutamide) by mouth for up to 2 weeks. This
      drug is being used to help decrease the risks of developing side effects due to the hormone
      injections (this is the standard of care with hormone treatments). You will take imatinib
      mesylate capsules every day for 6 weeks starting with the hormone treatments. You will also
      receive treatment with docetaxel. Docetaxel injections are given by vein over 60 minutes once
      a week for 4 weeks in a row. This will be followed by 2 weeks with no docetaxel. This 6 week
      period is considered a course of treatment. You will have up to 3 courses of treatment (18
      weeks) with docetaxel. After this treatment is complete, you will have prostate surgery
      within 4 weeks or when you have fully recovered from treatment.

      During treatment, your general health will be monitored and you will have physical exams and
      blood tests (about 1-2 tablespoons) often to make sure that you are tolerating the treatment
      safely. If the disease gets worse or you experience intolerable side effects, you will be
      taken off the study and your doctor will discuss other treatment options with you.

      Before surgery, you will be given a general anesthetic. An incision (cut) will be made in
      your abdomen (lower stomach area) and your prostate gland and lymph nodes in the pelvis will
      be removed. Before the procedure, the risks will be explained to you and you will need to
      sign a separate consent form.

      After surgery, you will have check-up visits every 3 months for 1 year, then every 6 months
      for the rest of your life. At these visits, you will have a physical exam and around 1-2
      tablespoons of blood collected for routine lab tests. If your doctor feels it is necessary,
      you may also have CT scans, bone scans, and/or x-rays. These tests are being done to check if
      the cancer has come back. If the cancer comes back, you will be removed from the study and
      your doctor will discuss treatment options with you.

      This is an investigational study. The leuprolide or goserelin acetate injections,
      bicalutamide tablets, imatinib mesylate capsules, and docetaxel injections are all FDA
      approved and are commercially available. Up to 36 participants will take part in this study.
      All will be enrolled at UT MD Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Pathological Complete Response</measure>
    <time_frame>Every 3 months for 1 year, then every 6 months until disease progression or death</time_frame>
    <description>Probability of response, defined as pathological complete remission based on tissue obtained at surgery. Pathological Complete Response (pCR): Patients without gross or microscopic evidence of residual disease at Radical Prostatectomy defined as pCR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Hormonal Ablation, Imatinib + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.</description>
    <arm_group_label>Hormonal Ablation, Imatinib + Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>600 mg by mouth (PO) Daily x 42 Days.</description>
    <arm_group_label>Hormonal Ablation, Imatinib + Docetaxel</arm_group_label>
    <other_name>Gleevec</other_name>
    <other_name>STI571</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>Hormone injections given every other month or every 3 months, as determined by the doctor.</description>
    <arm_group_label>Hormonal Ablation, Imatinib + Docetaxel</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Hormone injections given every other month or every 3 months, as determined by the doctor.</description>
    <arm_group_label>Hormonal Ablation, Imatinib + Docetaxel</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with adenocarcinoma of the prostate that in the opinion of the surgeon is
             resectable. Ductal adenocarcinoma of the prostate is included.

          -  All patients must be regarded as low anesthetic risk for radical prostatectomy and
             confirm their intention to undergo radical prostatectomy at the end of the neoadjuvant
             therapy.

          -  All patients must have at least one of the following high-risk features: clinical or
             pathological T3 disease, or cT2c or PSA&gt;20ng/ml or Gleason 8-10 adenocarcinoma or
             clinical T2b and PSA&gt;10ng/ml and Gleason 7 adenocarcinoma. The 1992 AJCC staging
             system will be followed.

          -  Prior hormonal therapy up to 2 months is permitted; no concurrent ketoconazole is
             permitted.

          -  Patients must have adequate bone marrow function defined as an absolute peripheral
             granulocyte count of &gt;/= 1,500/mm3 and platelet count of &gt;/= 100,000/mm3; adequate
             hepatic function defined with a total bilirubin of &lt;/= 1.5 mg/dl and aspartate
             aminotransferase (AST or SGOT)/alanine aminotransferase (ALT or SGPT) &lt;/= 2 times the
             upper limits of normal; adequate renal function defined as serum creatinine clearance
             &gt;/= 40 cc/min (measured or calculated).

          -  Patients must sign a written informed consent form prior to treatment. All patients
             must have a surgical and medical oncology consult prior to signing informed consent.

        Exclusion Criteria:

          -  Patients with small cell or sarcomatoid prostate cancers are not eligible.

          -  Patients with clinical or radiological evidence of metastatic disease

          -  Prior chemotherapy or experimental agents

          -  Patients with severe intercurrent infection.

          -  Patients with The New York Heart Association (NYHA) Class III/IV congestive heart
             failure, unstable angina or myocardial infarction (MI) in the last 6 months.

          -  Contraindications to corticosteroids.

          -  Uncontrolled severe hypertension, uncontrolled diabetes mellitus, oxygen-dependent
             lung disease, chronic liver disease or human immunodeficiency virus (HIV) infection.

          -  Second malignancies (excluding non-melanoma skin cancer) unless disease-free for 3
             years.

          -  Overt psychosis, mental disability or otherwise incompetent to give informed consent
             or history of non-compliance.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Mathew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <results_reference>
    <citation>Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan;181(1):81-7; discussion 87. doi: 10.1016/j.juro.2008.09.006. Epub 2008 Nov 13.</citation>
    <PMID>19012911</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <results_first_submitted>July 11, 2011</results_first_submitted>
  <results_first_submitted_qc>July 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2011</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Hormonal Ablation</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Imatinib Mesylate</keyword>
  <keyword>STI571</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Taxotere</keyword>
  <keyword>Goserelin Acetate</keyword>
  <keyword>Zoladex</keyword>
  <keyword>Leuprolide</keyword>
  <keyword>Lupron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment at Medical Clinic from 6/13/03 to 11/29/04.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hormonal Ablation, Imatinib + Docetaxel</title>
          <description>Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hormonal Ablation, Imatinib + Docetaxel</title>
          <description>Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Pathological Complete Response</title>
        <description>Probability of response, defined as pathological complete remission based on tissue obtained at surgery. Pathological Complete Response (pCR): Patients without gross or microscopic evidence of residual disease at Radical Prostatectomy defined as pCR.</description>
        <time_frame>Every 3 months for 1 year, then every 6 months until disease progression or death</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Pathological Complete Response</title>
          <description>Probability of response, defined as pathological complete remission based on tissue obtained at surgery. Pathological Complete Response (pCR): Patients without gross or microscopic evidence of residual disease at Radical Prostatectomy defined as pCR.</description>
          <population>Analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hormonal Ablation, Imatinib + Docetaxel</title>
          <description>Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis/embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine transaminase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Quality Assurance Specialist</name_or_title>
      <organization>MD Anderson Cancer Center</organization>
      <phone>713-563-1602</phone>
      <email>caperez@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

